CardiaCare recently announced it signed a strategic licensing agreement with Dr. Reddy’s Laboratories to further develop CardiaCare’s wearable atrial fibrillation treatment device. Through the agreement, Dr. Reddy’s Laboratories will lead necessary clinical studies for CardiaCare to receive regulatory clearance in India. CardiaCare is developing a non-invasive, personalized neuromodulation wearable for atrial fibrillation treatment. It will…
34 of the most innovative pharmaceutical products
The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Elyxyb remains a novel migraine therapy
Last year, FDA approved the celecoxib oral solution Elyxyb from Dr. Reddy’s Laboratories as an acute treatment of migraine with or without aura in adults. Formerly known as DFN-15, Elyxyb is a novel selective inhibitor of cyclooxygenase-2. The company received FDA approval for the drug in May 2020. The company formulated the drug as an oral solution…